Skip to main content

Adc Therapeutics Sa(ADCT-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low4.84
Day High5.08
Open:5.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
Business Wire - Wed Sep 21, 6:00PM CDT
Business Wire
Wed Sep 21, 6:00PM CDT
ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA ® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO...
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Business Wire - Fri Sep 16, 6:15AM CDT
Business Wire
Fri Sep 16, 6:15AM CDT
ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing...
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
Business Wire - Wed Sep 14, 10:17AM CDT
Business Wire
Wed Sep 14, 10:17AM CDT
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT ) for violations of the securities laws.